Collaboration, License and Other Agreements - Pfizer Collaboration (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
License and other agreements
Revenue		$ 215,079	$ 92,933	$ 533,931	$ 136,756
Collaboration and other revenue
License and other agreements
Revenue		21,125	0	216,387	0
Product revenue, net
License and other agreements
Revenue		193,954	$ 92,933	317,544	$ 136,756
Collaborative arrangement | Collaboration and other revenue
License and other agreements
Revenue		20,000
Pfizer
License and other agreements
Proceeds from sale of stock	$ 350,000
Number of shares sold in transaction (in shares)	2,022,581
Estimated fair value of shares issued	$ 252,000
Share purchase premium received	98,000
Pfizer | Collaborative arrangement
License and other agreements
Upfront payment received	150,000
Share purchase premium received	98,000
Eligible contingent payments receivable per agreement for sales-based milestones	740,000
Revenue		20,000
Contract liability	$ 53,611	51,009		51,009
Contract liability, current		18,990		18,990
Contract liability, noncurrent		32,019		32,019
Pfizer | Collaborative arrangement | Maximum
License and other agreements
Agreement term after first commercial sale	10 years
Pfizer | Collaborative arrangement | Revenue from Contract with Customer, Excluding Assessed Tax
License and other agreements
Revenue recognized that was previously in contract liability		1,729		2,602
Pfizer | Collaborative arrangement | Collaboration and other revenue
License and other agreements
Revenue				194,389
Revenue recognized that was previously in contract liability		1,125		1,998
Pfizer | Collaborative arrangement | Product revenue, net
License and other agreements
Revenue recognized that was previously in contract liability		$ 604		$ 604